For many adults living with type 2 diabetes, checking blood sugar has traditionally meant finger-prick tests a few times a day and long gaps in between with no information at all. A major new clinical trial suggests that continuous glucose monitors (CGMs) — the small wearable sensors long associated with insulin users — can make a substantial difference for people who do not use insulin either.
According to a summary of the research from the University of Colorado Anschutz Medical Campus, the trial — described as the largest of its kind and published in the New England Journal of Medicine — found that adults using a CGM spent roughly five more hours each day within their target blood sugar range than those relying on standard care.
Why Those Extra Hours Matter
Doctors measure diabetes control not only through single readings but through “time in range” — the share of the day blood sugar stays within a healthy band. More time in range is linked with a lower risk of the complications that make diabetes so serious over time, including damage to the eyes, kidneys, nerves and cardiovascular system. Gaining around five extra hours a day in that zone is therefore not a marginal improvement; compounded over months and years, it represents a meaningful shift in daily health.
Just as important is what happens between readings. Finger-prick testing shows a single moment. A CGM shows a trend: whether levels are rising after a meal, dipping overnight, or responding to a walk. That feedback loop helps patients connect everyday choices — food portions, sleep, activity, medication timing — with their effects in near real time.
Technology Is Changing Everyday Care
The findings fit a broader pattern we have covered before: digital tools are reshaping how health information reaches ordinary readers and patients, a theme explored in our look at the digital publishing and science communication boom. When research is communicated clearly and devices present data in a simple graph rather than a lab report, people are far more likely to act on it.
Rest and recovery are part of that picture too. Poor sleep can worsen glucose control, which is one reason interest is growing in recovery-focused habits — see our recent piece on sleep tourism and why travellers are booking holidays just to rest. For someone newly using a CGM, watching an overnight glucose trace can be the first concrete evidence of how sleep and late meals affect their body.
Who Stands to Benefit Most?
The trial focused on adults with type 2 diabetes who were not using insulin — a very large group that has historically had limited access to CGM technology, partly because insurers and health systems often restricted coverage to insulin users. If the results hold up in wider practice, they strengthen the case for broader coverage and for doctors to offer sensors earlier in the course of the disease, rather than only after complications appear.
There are still practical questions. Sensors cost money, need replacing every one to two weeks depending on the model, and generate a lot of data that can overwhelm some users. Clinics also need time and systems to review that data with patients. A device alone is not a treatment plan; it works best alongside medical guidance, nutrition support and realistic goals.
What Patients Should Ask Their Doctor
If you have type 2 diabetes and are curious about a CGM, useful questions include: Am I eligible under my insurance or local health system? Which target range is right for me personally? How often should we review my data together? And what changes — to food, activity or medication — should I actually make when I see a spike or a dip?
It is also worth setting expectations. A CGM will not lower blood sugar by itself; it makes the invisible visible. The benefit comes from the small, repeated adjustments that visibility makes possible: a shorter post-dinner walk taken because you can see it working, or a breakfast swapped because the trace shows what it does to your morning.
The Bottom Line
The largest trial of its kind indicates that continuous glucose monitoring is not just for people on insulin. For adults with type 2 diabetes, wearing a sensor was associated with about five additional hours a day in a healthy blood sugar range — a gain that could translate into fewer complications and better quality of life over time. As sensors become cheaper and easier to wear, this technology looks set to become a standard part of diabetes care rather than a specialist extra. Anyone considering one should discuss it with their own clinician, who can judge whether it fits their treatment plan.
